[Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
Interleukin-2 (Il-2) is widely used for treatment of carcinomas, leukemia, and melanoma. Adverse drug effects of Il-2 include various systemic and generalized cutaneous drug reactions. In the following we report on a persistent inflammatory reaction at the injection site of Il-2. A patient received chemoimmuno-therapy for treatment of metastasizing melanoma, including subcutaneous application of recombinant interleukin-2 (Proleukin((R))). Within a few days reddish nodules developed at the injection sites that persisted after cessation of Il-2 injections for two years until final lethal outcome. Histologic examination revealed a lobular panniculitis expressing atypical lymphocytes and multinucleated histiocytes.
Assmann
K
K
Universitäts-Hautklinik Münster, Germany. assmannk@uni-muenster.de
Nashan
D
D
Grabbe
S
S
Luger
T A
TA
Metze
D
D
D000368:Aged; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D017730:Ki-1 Antigen / Q000032:analysis; D016410:Lymphoma, T-Cell, Cutaneous / Q000139:chemically induced* / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D010166:Palliative Care; D015434:Panniculitis / Q000139:chemically induced / Q000473:pathology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy*
D007376:Interleukin-2; D017730:Ki-1 Antigen; D011994:Recombinant Proteins; C082598:aldesleukin